Dechra Pharmaceuticals plc

09/11/2019 | Press release | Distributed by Public on 09/11/2019 05:15

Opening of its solar power plant in Croatia & CMD

Wednesday, 11 September 2019

Dechra officially opens its solar powered facility -

the largest integrated power plant in Croatia

This week Dechra Pharmaceuticals PLC (Dechra) has seen the official opening of its solar powered plant at its subsidiary's Genera d.d. (Genera) manufacturing operation in Zagreb, Croatia.

At a cost of £1.3 million, which has been partially subsidised by EU funds, the Emissary of Prime Minister of the Republic of Croatia has announced that this is a very important solar renewable energy project in Croatia with 5,543 photovoltaic (PV) panels being fitted onto the existing roof structures across the Genera site.

The facility is now recognised as the largest integrated power plant for own consumption in Croatia. Any surplus electricity from the power plant is distributed to the municipal electrical grid.

The power plant project has taken seven months to complete and was commissioned in June this year. Up until then the Genera operation sourced 100% of energy via the main grid. Following the installation, the annualised level of electric power generation is expected to be approximately 1,545,000 kWh and will generate nearly a third of the electric power needed for Dechra's Croatian manufacturing facility.

Dechra's Chief Executive Officer Ian Page said:

'We are delighted with the outcome of this investment project and would like to thank everyone involved including the Genera staff, local partners, EU and government teams. This power plant initiative will see us de-risk the site's energy supply by securing its own source of electricity via renewable sources.

We expect to reduce the Zagreb site's CO2 footprint by approximately 360 tonnes, which equates to 4% of the Dechra's total CO2 emissions in 2018. We also anticipate that the power plant will allow us to lower variable costs, mitigate the risks of electricity price fluctuations, and will have a direct impact on reducing the cost of goods sold in the future.

Over the next five years we will be increasing manufacturing volume so, it is especially important from both a business and environmental perspective to utilise a renewable and sustainable energy source.'

Image shows: Genera d.d., Zagreb, Croatia

For further information, please contact:

Melanie Hall

Company Secretary

Telephone: +44 (0) 1606 814730

e-mail: [email protected]

Editor's Note:

Leading the celebrations on Tuesday 10 September were, MLADEN VEDRIŠ President of the Supervisory Board of Genera d.d. and MARKO FRESL, a Member of the Management Board of Genera d.d. They were joined by Dechra's Chief Executive Officer, IAN PAGE together with several of the Senior Executive Team and around 245 local staff.

In addition, 80 external guests and officials joined the celebratory day including: DOMAGOJ VALIDŽIĆ,Emissary of Prime Minister of the Republic of Croatia, TOMISLAV PINTER, Representative of Ministry of Regional Development and EU Funds, STJEPAN KOŽIĆMayor of Zagreb County; DARIO ZUROVEC, Mayor of Sveta Nedjelja City, SAŠA KRAMAR Member of the Management Board of the Croatian Telecom Inc.

Capital Markets Day

Dechra is hosting a Capital Markets Day for investors at the Zagreb facility today (Wednesday 11 September). No new material disclosures will be made during the event. Our next update to the market will be at the Trading update at the time of the Annual General Meeting on 18 October 2019.

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacture and sales and marketing of high-quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit:

Stock Code: London Stock Exchange: Full Listing (Pharmaceuticals): DPH